Seeking Alpha
27 Oct 2025, 11:00 UTC · 46w ago
Verdict
Headline takes no side. We score DGX +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The PATHFINDER 2 study confirms that GRAIL's multi-cancer early detection works effectively at scale.
More positive than 98% of claims this week
GRAIL secured $435 million in new funding, including strategic backing from Samsung for Asian market expansion.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 91% of claims this week
The company is accelerating adoption through partnerships with Quest Diagnostics, telemedicine providers, and employer health programs.
So whatStrategic distribution partnerships lower customer acquisition costs and increase the total addressable market.
More positive than 85% of claims this week
Which stocks this story touches
More positive than 35% of relationship scores this week
[mutual] GRAIL (subsidiary of Illumina/DGX) has partnerships with Quest Diagnostics to support physician and patient adoption.
More positive than 15% of relationship scores this week
[mutual] Samsung provided strategic backing to GRAIL for expansion into Asian markets.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
+36.0%
Price agrees with the score
$247.71 vs $182.18 close before publication (Oct 24) · not market-adjusted
DGX chart →
